Hepatocellular carcinoma and hepatitis C in the United States

被引:358
作者
El-Serag, HB
机构
[1] Houston Dept Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA
[2] Houston Dept Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA
[3] Baylor Coll Med, Houston, TX 77030 USA
关键词
D O I
10.1053/jhep.2002.36807
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Chronic infection with hepatitis C virus (HCV) is a major risk factor for development of hepatocellular carcinoma (HCC). In general, HCC develops only after 2 or more decades of HCV infection and the increased risk is restricted largely to patients with cirrhosis or advanced fibrosis. Factors that predispose to HCC among HCV-infected persons include mate sex, older age, hepatitis B virus (HBV) coinfection, heavy alcohol intake, and possibly diabetes and a transfusion-related source of HCV infection. Viral factors play a minor role. The likelihood of development of HCC among HCV-infected persons is difficult to determine because of the paucity of adequate long-term cohort studies; the best estimate is 1% to 3% after 30 years. Once cirrhosis is established, however, HCC develops at an annual rate of 1% to 4%. Successful antiviral therapy of patients with HCV-related cirrhosis may reduce the future risk for HCC. The incidence of and mortality caused by all HCC has doubled in the United States over the past 25 years, an increase that has affected all ethnic groups, both sexes, and younger age groups. Given the current prevalence of HCV infection among persons 30 to 50 years of age, the incidence and mortality rates of HCC are likely to double in the United States over the next 10 to 20 years. Future research should focus on improving understanding of the incidence and risk factors for HCC, causes of HCV-related carcinogenesis, means of early detection, and better treatment for HCC.
引用
收藏
页码:S74 / S83
页数:10
相关论文
共 93 条
  • [1] Excess risk of primary liver cancer in patients with diabetes mellitus
    Adami, HO
    Chow, WH
    Nyren, O
    Berne, C
    Linet, MS
    Ekbom, A
    Wolk, A
    McLaughlin, JK
    Fraumeni, JF
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (20) : 1472 - 1477
  • [2] Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity
    Adinolfi, LE
    Gambardella, M
    Andreana, A
    Tripodi, MF
    Utili, R
    Ruggiero, G
    [J]. HEPATOLOGY, 2001, 33 (06) : 1358 - 1364
  • [3] Epidemiology of hepatitis C
    Alter, MJ
    [J]. HEPATOLOGY, 1997, 26 (03) : S62 - S65
  • [4] The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States
    Armstrong, GL
    Alter, MJ
    McQuillan, GM
    Margolis, HS
    [J]. HEPATOLOGY, 2000, 31 (03) : 777 - 782
  • [5] Attributable risks for hepatocellular carcinoma in Northern Italy
    Braga, C
    LaVecchia, C
    Negri, E
    Franceschi, S
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (04) : 629 - 634
  • [6] Hepatocellular carcinoma occurring in nonfibrotic liver:: Epidemiologic and histopathologic analysis of 80 French cases
    Bralet, MP
    Régimbeau, JM
    Pineau, P
    Dubois, S
    Loas, G
    Degos, F
    Valla, D
    Belghiti, J
    Degott, C
    Terris, B
    [J]. HEPATOLOGY, 2000, 32 (02) : 200 - 204
  • [7] BRUIX J, 1989, LANCET, V2, P1004
  • [8] Brunetto MR, 1998, LANCET, V351, P1535
  • [9] Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study
    Bruno, S
    Silini, E
    Crosignani, A
    Borzio, F
    Leandro, G
    Bono, F
    Asti, M
    Rossi, S
    Larghi, A
    Cerino, A
    Podda, M
    Mondelli, MU
    [J]. HEPATOLOGY, 1997, 25 (03) : 754 - 758
  • [10] Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C
    Bruno, S
    Battezzati, PM
    Bellati, G
    Manzin, A
    Maggioni, M
    Crosignani, A
    Borzio, M
    Solforosi, L
    Morabito, A
    Ideo, G
    Podda, M
    [J]. JOURNAL OF HEPATOLOGY, 2001, 34 (05) : 748 - 755